ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer

Conditions

• Pancreatic Cancer
• Adenocarcinoma

Interventions

• DRUG: ARQ 501 in combination with gemcitabine

Sponsor

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)